08:09 AM EDT, 09/18/2025 (MT Newswires) -- Aurora Cannabis ( ACB ) , up 1.4% in the U.S. pre-market trading, Thursday said it is investing into operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany, to boost flower growth capacity, product quality and drive cost efficiency.

The improvements will take five years to complete. Aurora did not provide financial details.

"This investment marks a significant milestone in our commitment to operational excellence and long-term growth in Europe," said Alex Miller, who heads operations, science and supply chain at Aurora.

"These upgrades will strengthen our supply chain resilience, expand our domestic capabilities in EU-GMP certified manufacturing, and position us to best meet the growing demand for high-quality medical cannabis in Europe with precision and efficiency."

Aurora Leuna is one of three licensed cultivation facilities in Germany and supplies locally grown medical cannabis. It currently grows cultivars under the IndiMed brand, and the expansion will enable the site to grow additional cultivars available from Aurora's genetics library.

Aurora Cannabis ( ACB ) shares are up $0.07, to $5.06 in New York trading.